98%
921
2 minutes
20
Myasthenia gravis (MG) is an autoimmune disease mediated by autoantibodies. The important roles of circRNAs modified by m6A methylation have been reported in the pathogenesis of other autoimmune diseases, but remain unclear in MG. To address this point, we collected peripheral blood mononuclear cells from six MG patients and six healthy controls and performed m6A‑circRNA epitranscriptomic microarray and RNA sequencing. Differentially m6A-modified circRNAs and differentially expressed genes (DEGs) were analyzed. A network was constructed containing 17 circRNAs, 30 miRNAs, and 34 DEGs. The GSE85452 dataset was downloaded. DEGs that were differentially expressed in the GSE85452 dataset were selected as seed genes. Finally, four candidate m6A-modified circRNAs (hsa_circ_0084735, hsa_circ_0018652, hsa_circ_0025731, and hsa_circ_0030997) were identified through a random walk with restart. We found that they had different degree correlations with different immune cells. The results of MeRIP-qPCR showed that the m6A methylated levels of hsa_circ_0084735 and hsa_circ_0025731 were downregulated in MG patients, while the other two circRNAs were not significantly different between MG and control group. For the first time, we explored the pathogenesis of MG at the epigenetic transcriptome level. Our results will open new perspectives for MG research and identify potential biomarkers and therapeutic targets for MG.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12035-024-04352-9 | DOI Listing |
Cell Death Discov
August 2025
Department of Urology and Andrology, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China.
RNA modifications are widely distributed in almost all types of RNA, including mRNA, rRNA, miRNA, circRNA, and lncRNA, which are deeply involved in disease initiation and progression and are emerging therapeutic targets in diseases such as cancer, among which N6-methyladenosine (m6A) is the most abundant mRNA modification. Accumulating studies have demonstrated the critical role of m6A during cancer progression and its therapeutic potential in prostate cancer, which is one of the most common malignancies in men worldwide. Here, we reviewed the emerging roles of m6A regulators, including readers, writers, and erasers, and the downstream m6A-modified mRNA and noncoding RNA in prostate cancer.
View Article and Find Full Text PDFBMC Biol
August 2025
Department of Biochemistry and Molecular Biology, Binzhou Medical University, YanTai, Shandong, 264003, People's Republic of China.
Background: Communication between cancer cells and tumor microenvironment (TME) plays a complicated role in cancer malignancy. Circular RNAs (circRNAs), known for their stability and conservation, contribute to TME remodeling in various cancers. This study aims to investigate the role of N6-methyladenosine (m6A)-modified circZNF548 in the proliferation and migration of non-small cell lung cancer (NSCLC) within the TME.
View Article and Find Full Text PDFInt J Mol Med
October 2025
Department of Orthopedics, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518035, P.R. China.
N6‑methyladenosine (m6A) RNA modification represents a pivotal and novel post‑transcriptional modification in eukaryotic RNAs. Initially identified in messenger RNAs (mRNAs), m6A modification on these transcripts regulates a spectrum of essential cellular processes, including mRNA splicing, subcellular localization, stability and translation. Recent studies have highlighted the involvement of m6A methylation in both biological and pathological processes, particularly in cancer.
View Article and Find Full Text PDFJ Physiol Biochem
August 2025
Cancer Center, Renmin Hospital of Wuhan University, No.99, Zhangzhidong Road, Wuhan, 430060, Hubei, China.
Hepatocellular carcinoma (HCC) is known for its aggressive nature and high mortality rates. Circular RNAs (circRNAs) have emerged as critical regulators of cancer progression, yet the role of the circRNA cell division cycle and apoptosis regulator 1 (circCCAR1) in HCC is poorly understood. This study aims to explore the mechanism of circCCAR1 in HCC progression.
View Article and Find Full Text PDFFront Mol Med
June 2025
Department of Medicine, Division of Pulmonary and Critical Care Medicine, Boston University, Boston, MA, United States.
N6-methyladenosine (m6A) is the best-studied post-transcriptional RNA modification. It refers to the methylation in the N6 position. M6A exists universally from viruses to mammalian cells and is highly abundant in RNA polymerase II-transcribed, protein-coding transcripts and various non-coding RNAs.
View Article and Find Full Text PDF